menu
    • menu

    Company profile for Amicus Therapeutics

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Amicus Therapeutics, Inc. (Nasdaq:FOLD) is a global biotechnology company at the forefront of advanced therapies to treat a range of devastating rare and orphan diseases. We have a robust development pipeline of treatments for a range of human genetic diseases. Our lead product candidate, migalastat, is a personalized medicine in late-stage development to treat individuals with Fabry disease on the basis of their genetic di...
    Amicus Therapeutics, Inc. (Nasdaq:FOLD) is a global biotechnology company at the forefront of advanced therapies to treat a range of devastating rare and orphan diseases. We have a robust development pipeline of treatments for a range of human genetic diseases. Our lead product candidate, migalastat, is a personalized medicine in late-stage development to treat individuals with Fabry disease on the basis of their genetic diagnosis. Our lead biologics program is AT-GAA, a uniquely engineered Pompe disease ERT that will be administered in combination with a pharmacological chaperone.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Amicus TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1 Cedar Brook Drive Cranbury, NJ 08512
    Telephone
    Telephone
    +1 609-662-2000
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.amicusrx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/amicus-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Biomarin to Buy Amicus for $4.8 B in Rare Disease Bet
    Biomarin to Buy Amicus for $4.8 B in Rare Disease Bet

    19 Dec 2025

    // PRESS RELEASE

    https://investors.biomarin.com/news/news-details/2025/BioMarin-to-Acquire-Amicus-Therapeutics-for-4-8-Billion-Expanding-Position-as-a-Leader-in-Rare-Diseases-Accelerating-Revenue-Growth-and-Strengthening-Financial-Outlook/default.aspx

    PRESS RELEASE
    19 Dec 2025
    Share Share
    Amicus Therapeutics To Present At Investor Conferences
    Amicus Therapeutics To Present At Investor Conferences

    31 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/31/3178217/15991/en/Amicus-Therapeutics-to-Present-at-Upcoming-Investor-Conferences-in-November-2025.html

    GLOBENEWSWIRE
    31 Oct 2025
    Share Share
    Amicus Therapeutics To Report Q3 2025 Financial Results On Nov
    Amicus Therapeutics To Report Q3 2025 Financial Results On Nov

    23 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/23/3171888/15991/en/Amicus-Therapeutics-to-Announce-Third-Quarter-2025-Financial-Results-on-November-4-2025.html

    GLOBENEWSWIRE
    23 Oct 2025
    Share Share
    4-Year Data for Pombiliti and Opfolda Presented at ICIEM
    4-Year Data for Pombiliti and Opfolda Presented at ICIEM

    08 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/08/3146157/15991/en/New-4-Year-Data-for-Pombiliti-cipaglucosidase-alfa-atga-Opfolda-miglustat-Presented-at-ICIEM.html

    GLOBENEWSWIRE
    08 Sep 2025
    Share Share
    Amicus Therapeutics to Present at Investor Conferences
    Amicus Therapeutics to Present at Investor Conferences

    29 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/29/3141407/15991/en/Amicus-Therapeutics-to-Present-at-Upcoming-Investor-Conferences-in-September-2025.html

    GLOBENEWSWIRE
    29 Aug 2025
    Share Share
    Rare Disease Clinical Progress Boosts Long-Term Revenue Potential
    Rare Disease Clinical Progress Boosts Long-Term Revenue Potential

    07 Aug 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/clinical-progress-in-rare-disease-signals-long-term-revenue-potential-for-innovators-302523131.html

    PR NEWSWIRE
    07 Aug 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search